On February 10, 2016

UVM Vaccine Testing Center to play role in Zika virus vaccine development

Submitted

The University of Vermont Vaccine Testing Center will be involved in the development of a vaccine for Zika virus, which was declared a global health emergency by the World Health Organization on Feb. 1.

The University of Vermont Vaccine Testing Center (VTC) announced Feb. 4 that it will be involved in the development of a vaccine for Zika virus, which was declared a global health emergency by the World Health Organization on Feb. 1.

UVM VTC faculty Kristen Pierce, M.D., (KP) an infectious disease specialist and associate professor of medicine, and Sean Diehl, Ph.D., (SD) an immunologist and assistant professor of medicine, have expertise in the characteristics of flaviviruses – a group of viruses, mostly transmitted via insects, that cause such human diseases as Zika virus, yellow fever, dengue, various types of encephalitis, and hepatitis C – and related vaccines. An infectious disease physician, Pierce has led or co-led several dengue and West Nile virus vaccine-related trials. Diehl studies the basic mechanisms of flaviviruses, vaccines against flaviviruses, and the immune responses triggered by flavivirus natural infection or vaccination.

“The VTC has a long-standing partnership with the National Institutes of Health (NIH) lab that developed a dengue vaccine and is developing the Zika vaccine, and the VTC, together with the Center for Immunization Research at Johns Hopkins University in Baltimore, Md., will be one two sites to test the safety and immune response testing of an NIH-developed Zika vaccine candidate in humans. Because of the potential for a link of Zika infection with birth defects, pregnant women or those who may become pregnant will be excluded from Zika vaccine trials,” Pierce and Diehl said in a statement.

Do you want to submit feedback to the editor?

Send Us An Email!

Related Posts

Vt Legislature advances bill to ban toxic ‘forever chemicals’ from firefighting gear, dental floss, cleaning products

June 4, 2025
The Vermont Senate and House advance legislation (H.238) May 29 that would outlaw the use of toxic perfluoroalkyl and polyfluoroalkyl substances (PFAS) in firefighting gear, dental floss, cleaning products, and fluorine-treated containers—a critical step in reducing Vermonters’ exposure to these harmful substances. The Senate expanded the bill as passed by the House by adding a provision that…

To be continued…

June 4, 2025
A final compromise on education reform proved elusive late Friday, and at about 11 p.m., the Senate adjourned, followed by the House at about 11:30 p.m. As late as 10 p.m., legislative leaders were still hopeful that the six conferees (three House and three Senate members) could reach a deal sometime before midnight that would…

Nearing the end?

June 4, 2025
After passing several challenging bills in the last few weeks, the Vermont Legislature adjourned until June 16 due to an impasse over negotiations on our education transformation bill, H.454. Many other bills addressing housing, homelessness, healthcare, and several other major issues required compromises from both the House and the Senate in order to be passed…

Vermont gets $23 million from ongoing settlement with tobacco manufacturers

June 4, 2025
Attorney General Charity Clark announced last month that Vermont received a total of $23,132,483.92 from tobacco manufacturers under the tobacco Master Settlement Agreement (MSA). Annually, Vermont receives monies from tobacco manufacturers from the MSA, which resolved the state’s lawsuit filed in the 1990s. The settlement funds are credited to the state’s Tobacco Fund, and the…